Announcements Trials

Browse Landscape

Phase

Status

Unknown 1 Completed 1

Sponsor Class

Study Type

Interventional 1

Sponsor

Cancer Type

Conditions

Melanoma 4 Recurrence 1 Neoplasms 1 Neoplasm Metastasis 1 Lung Neoplasms 1

Interventions

Cyclophosphamide 17 fludarabine 13 Dexamethasone 12 Cisplatin 11 Rituximab 10 Gemcitabine 9 Paclitaxel 7 Lenalidomide 7 Decitabine 7 Cytarabine 7 Bendamustine Hydrochloride 7 fludarabine phosphate 6 N-(2-amino-5-fluorobenzyl)-4-(N-(pyridine-3-acrylyl)aminomethyl)benzamide 6 Etoposide 6 Carboplatin 6 Bortezomib 6 Radiotherapy 5 Injections 5 Azacitidine 5 camrelizumab 4 apatinib 4 Valproic Acid 4 Thalidomide 4 Procarbazine 4 Oxaliplatin 4 Drug Therapy 4 Antilymphocyte Serum 4 tislelizumab 3 pomalidomide 3 liposomal doxorubicin 3

Date Range

30 days 90 days 1 year All

Options

Has results Has announcements

Clinical Trials

1 trials

Recent Start date Enrollment

Unknown × Recurrence × binimetinib × Clear all

NCT04292119 2021-03-10

Lorlatinib Combinations in Lung Cancer

Massachusetts General Hospital

Phase 1/2 Unknown

Lung Neoplasms, Recurrence

Data powered by HemOnc (CC BY 4.0) Colophon ⚡